Study of Nivolumab for Advanced Cancers in India

• Status: Completed
• Trial end date: 2019-07-17
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of nivolumab in participants with advanced Non-Small Cell Lung Cancer or Kidney Cancer in India.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Antibodies, Monoclonal; Nivolumab

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy OR advanced renal cell carcinoma (RCC) after prior therapy

• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1

• Prior radiotherapy or radiosurgery must have been completed at least 2 weeks prior to randomization

Exclusion Criteria:

• Participants with untreated, symptomatic central nervous system (CNS) metastases

• Participants with carcinomatous meningitis

• Participants with active, known or suspected autoimmune disease

• Participants with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications

• Other active malignancy requiring concurrent intervention

Other protocol defined inclusion/exclusion criteria could apply